Literature DB >> 17675459

Cutting edge: trans-signaling via the soluble IL-6R abrogates the induction of FoxP3 in naive CD4+CD25 T cells.

Sabine Dominitzki1, Massimo C Fantini, Clemens Neufert, Alexei Nikolaev, Peter R Galle, Jürgen Scheller, Giovanni Monteleone, Stefan Rose-John, Markus F Neurath, Christoph Becker.   

Abstract

Chronic inflammatory diseases may develop when regulatory T cells (Tregs) fail to control the balance between tolerance and immunity. Alternatively, activated immune cells might prevent the induction or activation of Tregs in such diseases. In this study, we demonstrate that trans-signaling into T cells via the soluble IL-6 receptor completely abrogates the de novo induction of adaptive Tregs. Mechanistically, IL-6 trans-signaling augmented the expression of the TGF-beta signaling inhibitor SMAD7. Consequently, SMAD7 overexpression in T cells using newly created transgenic mice rendered CD4(+)CD25(-) T cells resistant to the induction of FoxP3. Finally, IL-6 trans-signaling inhibited Treg-mediated suppression in a murine model of colitis. In summary, IL-6 trans-signaling into T cells emerges as a key pathway for blockade of the development of adaptive Tregs and thus may play a pivotal role in shifting the balance between effector and regulatory T cell numbers in chronic inflammatory and autoimmune diseases.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17675459     DOI: 10.4049/jimmunol.179.4.2041

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  91 in total

1.  Tumor development in murine ulcerative colitis depends on MyD88 signaling of colonic F4/80+CD11b(high)Gr1(low) macrophages.

Authors:  Gabriela Schiechl; Bernhard Bauer; Ivan Fuss; Sven A Lang; Christian Moser; Petra Ruemmele; Stefan Rose-John; Markus F Neurath; Edward K Geissler; Hans-Jürgen Schlitt; Warren Strober; Stefan Fichtner-Feigl
Journal:  J Clin Invest       Date:  2011-04-25       Impact factor: 14.808

Review 2.  Epigenetic mechanisms of regulation of Foxp3 expression.

Authors:  Girdhari Lal; Jonathan S Bromberg
Journal:  Blood       Date:  2009-07-29       Impact factor: 22.113

3.  TGF-beta and IL-6 signals modulate chromatin binding and promoter occupancy by acetylated FOXP3.

Authors:  Arabinda Samanta; Bin Li; Xiaomin Song; Kathryn Bembas; Geng Zhang; Makoto Katsumata; Sandra J Saouaf; Qiang Wang; Wayne W Hancock; Yuan Shen; Mark I Greene
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-08       Impact factor: 11.205

Review 4.  Regulatory T cells as therapeutic targets in rheumatoid arthritis.

Authors:  Jonathan H Esensten; David Wofsy; Jeffrey A Bluestone
Journal:  Nat Rev Rheumatol       Date:  2009-10       Impact factor: 20.543

Review 5.  Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling.

Authors:  Simon A Jones; Jürgen Scheller; Stefan Rose-John
Journal:  J Clin Invest       Date:  2011-09-01       Impact factor: 14.808

Review 6.  Ubiquitous points of control over regulatory T cells.

Authors:  Fan Pan; Joseph Barbi
Journal:  J Mol Med (Berl)       Date:  2014-04-29       Impact factor: 4.599

7.  Myelin basic protein priming reduces the expression of Foxp3 in T cells via nitric oxide.

Authors:  Saurav Brahmachari; Kalipada Pahan
Journal:  J Immunol       Date:  2010-01-18       Impact factor: 5.422

8.  Green tea epigallocatechin-3-gallate modulates differentiation of naïve CD4⁺ T cells into specific lineage effector cells.

Authors:  Junpeng Wang; Munkyong Pae; Simin Nikbin Meydani; Dayong Wu
Journal:  J Mol Med (Berl)       Date:  2012-10-12       Impact factor: 4.599

9.  Antagonism of airway tolerance by endotoxin/lipopolysaccharide through promoting OX40L and suppressing antigen-specific Foxp3+ T regulatory cells.

Authors:  Wei Duan; Takanori So; Michael Croft
Journal:  J Immunol       Date:  2008-12-15       Impact factor: 5.422

10.  Genotype-dependent tumor regression in Marek's disease mediated at the level of tumor immunity.

Authors:  Shyamesh Kumar; Joram J Buza; Shane C Burgess
Journal:  Cancer Microenviron       Date:  2009-03-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.